These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 25802515)

  • 1. Interval cancers in a population-based screening program for colorectal cancer in catalonia, Spain.
    Garcia M; Domènech X; Vidal C; Torné E; Milà N; Binefa G; Benito L; Moreno V
    Gastroenterol Res Pract; 2015; 2015():672410. PubMed ID: 25802515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing.
    van der Vlugt M; Grobbee EJ; Bossuyt PMM; Bos A; Bongers E; Spijker W; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Gastroenterology; 2017 Aug; 153(2):439-447.e2. PubMed ID: 28483499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The sensitivity, specificity, predictive values, and likelihood ratios of fecal occult blood test for the detection of colorectal cancer in hospital settings.
    Elsafi SH; Alqahtani NI; Zakary NY; Al Zahrani EM
    Clin Exp Gastroenterol; 2015; 8():279-84. PubMed ID: 26392783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interval cancers in a FOBT-based colorectal cancer population screening programme: implications for stage, gender and tumour site.
    Steele RJ; McClements P; Watling C; Libby G; Weller D; Brewster DH; Black R; Carey FA; Fraser CG
    Gut; 2012 Apr; 61(4):576-81. PubMed ID: 21930729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Oral and Upper Gastrointestinal Cancers in Persons With Positive Results From a Fecal Immunochemical Test in a Colorectal Cancer Screening Program.
    van der Vlugt M; Grobbee EJ; Bossuyt PM; Bos ACRK; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Clin Gastroenterol Hepatol; 2018 Aug; 16(8):1237-1243.e2. PubMed ID: 29427732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The detection of interval colorectal cancers following screening by fecal immunochemical test may predict worse outcomes and prompt ethical concerns: a 6-year population-based cohort study in a full district.
    Asteria CR; Lucchini G; Guarda L; Ricci P; Pagani M; Boccia L
    Eur J Cancer Prev; 2019 Jan; 28(1):17-26. PubMed ID: 29111981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated screening for colorectal cancer with fecal occult blood test in Catalonia, Spain.
    Garcia M; Borràs JM; Binefa G; Milà N; Espinàs JA; Moreno V
    Eur J Cancer Prev; 2012 Jan; 21(1):42-5. PubMed ID: 21849903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of lung cancer through low-dose CT screening (NELSON): a prespecified analysis of screening test performance and interval cancers.
    Horeweg N; Scholten ET; de Jong PA; van der Aalst CM; Weenink C; Lammers JW; Nackaerts K; Vliegenthart R; ten Haaf K; Yousaf-Khan UA; Heuvelmans MA; Thunnissen E; Oudkerk M; Mali W; de Koning HJ
    Lancet Oncol; 2014 Nov; 15(12):1342-50. PubMed ID: 25282284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interval cancers in a guaiac-based colorectal cancer screening programme: Consequences on sensitivity.
    Blom J; Törnberg S
    J Med Screen; 2017 Sep; 24(3):146-152. PubMed ID: 28142309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Faecal occult blood testing screening for colorectal cancer and 'missed' interval cancers: are we ignoring the elephant in the room? Results of a multicentre study.
    George AT; Aggarwal S; Dharmavaram S; Menon A; Dube M; Vogler M; Field A
    Colorectal Dis; 2017 May; 19(5):O108-O114. PubMed ID: 27992095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interval cancers after negative immunochemical test compared to screen and non-responders' detected cancers in Slovenian colorectal cancer screening programme.
    Mlakar DN; Bric TK; Škrjanec AL; Krajc M
    Radiol Oncol; 2018 Jul; 52(4):413-421. PubMed ID: 30511936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of uptake in a biennial faecal occult blood test screening programme for colorectal cancer.
    Steele RJ; McClements PL; Libby G; Carey FA; Fraser CG
    Colorectal Dis; 2014 Jan; 16(1):28-32. PubMed ID: 24034143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
    Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
    Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes and cost evaluation of the first two rounds of a colorectal cancer screening program based on immunochemical fecal occult blood test in northern Italy.
    Parente F; Boemo C; Ardizzoia A; Costa M; Carzaniga P; Ilardo A; Moretti R; Cremaschini M; Parente EM; Pirola ME
    Endoscopy; 2013; 45(1):27-34. PubMed ID: 23254404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interval cancers in a community-based programme of colorectal cancer screening with faecal occult blood test.
    Tazi MA; Faivre J; Lejeune C; Bolard P; Phelip JM; Benhamiche AM
    Eur J Cancer Prev; 1999 Apr; 8(2):131-5. PubMed ID: 10335459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Participation, yield, and interval carcinomas in three rounds of biennial FIT-based colorectal cancer screening.
    Stegeman I; van Doorn SC; Mundt MW; Mallant-Hent RC; Bongers E; Elferink MA; Fockens P; Stroobants AK; Bossuyt PM; Dekker E
    Cancer Epidemiol; 2015 Jun; 39(3):388-93. PubMed ID: 25910865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of the immunochemical fecal occult blood test for colorectal cancer screening in Brazil.
    Teixeira CR; Bonotto ML; Lima JP; Figueiredo LF; Conrado L; Frasca C
    Ann Gastroenterol; 2017; 30(4):442-445. PubMed ID: 28655982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammographic and clinical characteristics of different phenotypes of screen-detected and interval breast cancers in a nationwide screening program.
    Baré M; Torà N; Salas D; Sentís M; Ferrer J; Ibáñez J; Zubizarreta R; Sarriugarte G; Barata T; Domingo L; Castells X; Sala M
    Breast Cancer Res Treat; 2015 Nov; 154(2):403-15. PubMed ID: 26531756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mortality From Postscreening (Interval) Colorectal Cancers Is Comparable to That From Cancer in Unscreened Patients-A Randomized Sigmoidoscopy Trial.
    Jodal HC; Løberg M; Holme Ø; Adami HO; Bretthauer M; Emilsson L; Ransohoff DF; Hoff G; Kalager M
    Gastroenterology; 2018 Dec; 155(6):1787-1794.e3. PubMed ID: 30165051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Divergent Long-Term Detection Rates of Proximal and Distal Advanced Neoplasia in Fecal Immunochemical Test Screening Programs: A Retrospective Cohort Study.
    Zorzi M; Hassan C; Capodaglio G; Narne E; Turrin A; Baracco M; Dal Cin A; Fiore A; Martin G; Repici A; Rex D; Rugge M
    Ann Intern Med; 2018 Nov; 169(9):602-609. PubMed ID: 30285055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.